Abstract
Opportunities still exist for companies willing to work at making drug development work for them
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Edgington, S. Surviving the '90s: Can Biotech Master Clinical Trials?. Nat Biotechnol 12, 977–981 (1994). https://doi.org/10.1038/nbt1094-977
Issue Date:
DOI: https://doi.org/10.1038/nbt1094-977